Trials / Terminated
TerminatedNCT03505710
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab deruxtecan | Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion. |
Timeline
- Start date
- 2018-05-21
- Primary completion
- 2021-05-03
- Completion
- 2024-04-17
- First posted
- 2018-04-23
- Last updated
- 2025-05-30
- Results posted
- 2022-05-17
Locations
21 sites across 5 countries: United States, France, Japan, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03505710. Inclusion in this directory is not an endorsement.